The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...

The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...

Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...

Recent advances in the understanding of immune-mediated neurological disorders have led to a paradigm shift toward pathophysiology-directed therapies. Central to this progress is a deeper appreciation ...

The Cascade Theatre announced it's bringing back its annual holiday show, "A Cascade Christmas" on Nov. 21-23 and Nov. 28-30. This year's show follows the misadventures of three elves who accidentally ...

In breaking out a new sweater for the 2026 Winter Classic, the New York Rangers didn’t stray too far from their popular Centennial jersey, which was introduced before the start of this seasons, their ...

The 19th Diamond Classic Synchronized Skating Competition at the Mentor Ice Arena brought big crowds and 37 teams from across the country for an event that Chairperson Sue Clemente said she hopes will ...

SAN FRANCISCO -- The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized myasthenia gravis (MG), the phase II MaGic trial showed. The ...

Advances in immunopathology have led to targeted therapies for gMG, including complement inhibitors and FcRn antagonists, offering more precise treatment options. FDA-approved drugs for gMG include ...

The company can now initiate the Opti-GAIN (Optimized Geographic Atrophy INterventional) phase 1/2 clinical trial. The US Food and Drug Administration (FDA) has approved the Investigational New Drug ...